PRETERAX TABLETS

Država: Singapur

Jezik: engleski

Izvor: HSA (Health Sciences Authority)

Aktivni sastojci:

INDAPAMIDE; PERINDOPRIL TERT-BUTYLAMINE

Dostupno od:

SERVIER (S) PTE LTD

ATC koda:

C09BA04

Doziranje:

0.625 mg

Farmaceutski oblik:

TABLET

Sastav:

INDAPAMIDE 0.625 mg; PERINDOPRIL TERT-BUTYLAMINE 2 mg

Administracija rute:

ORAL

Tip recepta:

Prescription Only

Proizveden od:

LES LABORATOIRES SERVIER INDUSTRIE

Status autorizacije:

ACTIVE

Datum autorizacije:

1999-03-24

Uputa o lijeku

1
QUALITATIVE AND QUANTITATIVE COMPOSITION
Boxes of 30 scored tablets dosed at 2 mg of perindopril
tert-butylamine and 0.625 mg of indapamide.
THERAPEUTIC INDICATION
Essential hypertension.
POSOLOGY AND METHOD OF ADMINISTRATION
Oral route.
One PRETERAX tablet per day as a single dose, prefer-
ably to be taken in the morning and before a meal. If blood
pressure is inadequately controlled, the dose should be
doubled using two tablets of PRETERAX.
_ELDERLY_
Treatment should be started at the normal dose of one
PRETERAX tablet per day.
Patients with renal insufficiency (see section on special
warnings and special precautions for use).
In cases of severe renal insufficiency (creatinine clear-
ance < 30 ml/min), treatment is contra-indicated. In
patients with moderate renal insufficiency (creatinine
clearance 30-60 ml/min), the maximum dose should be
one tablet of PRETERAX per day. In patients with creati-
nine clearance greater than or equal to 60 ml/min, no
dose modification is required.
Usual medical follow-up will include frequent monitoring
of creatinine and potassium.
_CHILDREN_
PRETERAX should not be used in children as the efficacy
and tolerability of perindopril in children, alone or in com-
bination, have not been established.
CONTRA-INDICATIONS
_LINKED TO PERINDOPRIL_
This drug SHOULD NEVER be used in cases of:
•
hypersensitivity to perindopril, or to any other
angiotensin converting enzyme inhibitors,
•
previous history of angioneurotic oedema (Quincke's
oedema) linked to treatment with an angiotensin 
converting enzyme inhibitor,
•
hereditary or idiopathic angioneurotic oedema,
•
pregnancy,
•
lactation.
This drug is generally not recommended in :
•
combinations with potassium-sparing diuretics,
potassium salts, lithium (see section on Interactions
with other drugs and other forms of interaction),
•
bilateral renal artery stenosis or single functioning 
kidney,
•
hyperkalaemia
_LINKED TO INDAPAMIDE_
This drug SHOULD NEVER be used in cases of:
•
hypersensitivity to sulphon

Svojstava lijeka

1
QUALITATIVE AND QUANTITATIVE COMPOSITION
Boxes of 30 scored tablets dosed at 2 mg of perindopril
tert-butylamine and 0.625 mg of indapamide.
THERAPEUTIC INDICATION
Essential hypertension.
POSOLOGY AND METHOD OF ADMINISTRATION
Oral route.
One PRETERAX tablet per day as a single dose, prefer-
ably to be taken in the morning and before a meal. If blood
pressure is inadequately controlled, the dose should be
doubled using two tablets of PRETERAX.
_ELDERLY_
Treatment should be started at the normal dose of one
PRETERAX tablet per day.
Patients with renal insufficiency (see section on special
warnings and special precautions for use).
In cases of severe renal insufficiency (creatinine clear-
ance < 30 ml/min), treatment is contra-indicated. In
patients with moderate renal insufficiency (creatinine
clearance 30-60 ml/min), the maximum dose should be
one tablet of PRETERAX per day. In patients with creati-
nine clearance greater than or equal to 60 ml/min, no
dose modification is required.
Usual medical follow-up will include frequent monitoring
of creatinine and potassium.
_CHILDREN_
PRETERAX should not be used in children as the efficacy
and tolerability of perindopril in children, alone or in com-
bination, have not been established.
CONTRA-INDICATIONS
_LINKED TO PERINDOPRIL_
This drug SHOULD NEVER be used in cases of:
• hypersensitivity
to
perindopril,
or
to
any
other
angiotensin converting enzyme inhibitors,
• previous history of angioneurotic oedema (Quincke's
oedema) linked to treatment with an angiotensin
converting enzyme inhibitor,
• hereditary or idiopathic angioneurotic oedema,
• pregnancy,
• lactation.
This drug is generally not recommended in :
• combinations
with
potassium-sparing
diuretics,
potassium salts, lithium (see section on Interactions
with other drugs and other forms of interaction),
• bilateral renal artery stenosis or single functioning
kidney,
• hyperkalaemia
_LINKED TO INDAPAMIDE_
This drug SHOULD NEVER be used in cases of:
• hypersensitivity to sulphonamides,
• severe r